MilliporeSigma and genOway enter CRISPR collaboration

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Teka74)
(Image: Getty/Teka74)

Related tags: CRISPR, Collaboration, acquistion, Genome, Gene editing, preclinical, Preclinical contract research, Research, discovery services

genOway has acquired exclusive rights to MilliporeSigma's genome-editing patents to produce and sell new rodent models.

As per the agreement – financial details of which were not disclosed – the France-based research model developer GenOway will license MilliporeSigma’s CRISPR integration patents to develop new models that enable scientists to use CRISPR/Cas9 genome editing technology.

Additionally, GenOway will develop a network of sublicensees in model creation and distribution businesses. It also will It also will sublicense the technology for preclinical services.

The long-term research collaboration aims to develop new research tools, models, and platforms to expand MilliporeSigma’s intellectual property (IP) portfolio.

A spokesperson for MilliporeSigma told us that the alliance with genOway will enable the company to offer “custom world-class”​ animal models and services for both the pharmaceutical industry and academia.

“These models are critical components in identifying and studying physiologic and cellular targets and pathways for research and therapeutics,”​ the spokesperson explained. The disease models established per this collaboration can be used to study disease progression and pathway regulation.

Development of these models can shorten the time the industry spends testing safety and efficacy before moving to human clinical trials, the spokesperson said

Recently, Ncardia and Horizon Discovery​ entered a similar collaboration in which the companies used genetically-modified and differentiated human cells for drug discovery and preclinical models.

At the time Stefan Braam, CEO of Ncardia explained that drug delivery and development relies on pre-clinical model systems and that late-stage drug failures can be attributed to a lack of predictive pre-clinical models.

Related topics: Cell & Gene Therapies, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars